Medicina News – Informazione Medica

Tag: Heart Failure Newsletter

Cardiology News by Xagena

Scritto il
Pubblicato inMedicina

Updates in Cardiology

FDA ( Food and Drug Administration )

FDA: no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesartan in patients with diabetes

The FDA ( Food and Drug Administration ) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesart …

News

Patients with bicuspid aortic valve without Marfan syndrome: identification of fibrillin 1 gene mutations

Bicuspid aortic valve ( BAV ) is the most frequent congenital heart disease with frequent involvement in thoracic aortic dilatation, aneurysm and dissection. Although BAV and Marfan syndrome ( MFS ) share some clinical features, and some MFS … more

Angiotensin receptor neprilysin inhibitors: independence of the blood pressure lowering effect and efficacy of the LCZ696, in patients with heart failure with preserved ejection fraction

The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New York Heart Association ( NYHA ) class in … more

Anticoagulation with Warfarin offers a net benefit in patients with atrial fibrillation and renal failure

A study has evaluated if Warfarin provides net benefit in patients with atrial fibrillation and renal failure. The data in this retrospective study of 283,969 patients with atrial fibrillation were obtained by analysis of health care databases in … more

Cardiology Updates by Xagena

Scritto il
Pubblicato inMedicina

Updates in Cardiology

Top News / Myocardial infarction: Heparin vs Bivalirudin

–
” Even if Heparin alone had produced statistically similar outcomes to Bivalirudin, it would have been a win for Heparin. A drug that costs less than a 1/400th of another that has similar efficacy and safety ought to be used preferentially “  Peter Berger and James Blankenship of Geisinger Health System, in Pennsylvania, USA

Myocardial infarction: Heparin rather than Bivalirudin after primary percutaneous coronary intervention can improve outcomes and save health budgets millions

A new study has compared outcomes for two drugs used to prevent blood clot formation during emergency myocardial infarction treatment. The study suggests that use of one of the drugs, Heparin, could …
Focus On: Diabetes mellitus & Heart failure
Sitagliptin therapy has shown no sign of increasing risk for all-cause hospitalization or death ( primary end point ), but the use of Sitagliptin was associated with greater risk of hospitalization for heart failure

Sitagliptin linked to increased risk of heart failure-related hospitalizations among patients with type 2 diabetes with pre-existing heart failure

The study objective was to evaluate the effects of Sitagliptin ( Januvia ), a dipeptidyl peptidase 4 inhibitor, in patients with type 2 diabetes ( T2D ) and heart failure ( HF ). There is uncertain …

News

Benefits of percutaneous MitraClip device for mitral regurgitation in high-surgical-risk patients: EVEREST II trial

The EVEREST II ( Endovascular Valve Edge-to-Edge REpair Study ) High-Risk registry and REALISM Continued Access Study High-Risk Arm are prospective registries of patients who received the MitraClip de …

Nonselective agents with greater inhibition of Cox-1 than Cox-2, such as Ibuprofen, were not associated with increased cardiovascular risk

Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs ( NSAIDs ) are sparse. It has been hypothesized that regular NSAID use is associated with increased risk for cardi …

High-potency statin reduces mortality in survivors of an acute myocardial infarction

A study has determined all-cause mortality in patients with a first myocardial infarct who were treated with Simvastatin ( Zocor ) compared with high-potency statin and Simvastatin / Ezetimibe

Tema Seamless Keith, sviluppato da Altervista

Apri un sito e guadagna con Altervista - Disclaimer - Segnala abuso - Privacy Policy - Personalizza tracciamento pubblicitario